Eli Lilly's (LLY) Effient blood thinner surprisingly failed to perform better than Plavix, an...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly's (LLY) Effient blood thinner surprisingly failed to perform better than Plavix, an older drug, in study of 9,000 patients. While the outcome is a blow for the hopes of Eli Lilly and partner Daiichi Sankyo in expanding the use of Effient, it's good news for AztraZenica (AZN), whose Brilinta does have an edge over Plavix. The results were reported at the annual congress of the European Society of Cardiology.